<div id="readability-page-1" class="page">Telehealth company and Hims &amp; Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the “copycat” compounded versions it has long advertised. In a press release, Hims &amp; Hers said it will “no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers.” “We see tremendous growth opportunities in the US with the expanding assortment of branded GLP-1 medications,” said Andrew Dudum, co-founder and CEO of Hims &amp; Hers. “I’m excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people. This collaboration reflects what’s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.” Hims &amp; Hers will now offer FDA-approved semaglutide products, which include Novo Nordisk’s Ozempic and Wegovy, on a “limited scale.” This represents a drastic change for the online company that has attributed the sale of compounded GLP-1s as a significant driver of its growth. The company even purchased a compounding pharmacy in 2024. “This agreement with Hims &amp; Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,” Novo Nordisk President and CEO Mike Doustdar said in a statement. The collaboration between the two companies will offer both the injectable versions of semaglutide and the recently approved oral version of Wegovy. This is not the first time the two companies have attempted to cooperate. When semaglutide came out of shortage, Novo partnered with several telehealth platforms to offer its GLP-1 products. The company ended its partnership with Hims &amp; Hers soon after due to the telehealth platform continuing to offer compounded versions of Ozempic and Wegovy. Just last month, Novo Nordisk filed a lawsuit against Hims &amp; Hers for selling what it alleged to be “unapproved knock-off versions of Wegovy® and Ozempic®.” On Monday, attorneys for Novo Nordisk submitted a notice of voluntary dismissal regarding the lawsuit. This shift in its business model also comes as federal regulators have started to crack down on the sale of compounded GLP-1s. The Department of Health and Human Services had referred Hims &amp; Hers to the Justice Department for possible criminal violations and last week, the Food and Drug Administration sent out warning letters to 30 telehealth companies for the “illegal” marketing of compounded drugs.</div>

HIMS

NVOX

Hims & Hers has announced a strategic partnership with Novo Nordisk, ceasing the sale of compounded GLP-1 medications and transitioning to FDA-approved options like Ozempic and Wegovy. This shift aims to enhance access to safe and effective treatments, as federal regulators increase scrutiny on compounded drugs. CEO Andrew Dudum expressed optimism about growth opportunities in the U.S. market, while Novo Nordisk's CEO highlighted the collaboration as a win for patients. The partnership follows previous attempts to cooperate, which were hindered by Hims & Hers' continued sale of unapproved versions.

Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s